RARE CANCERGI CancerWHO 5th Edition Classification

Gastrointestinal Stromal Tumor (GIST)

Rare Malignancy (< 6 cases per 100,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

The commonest mesenchymal tumour of the digestive tract, arising from the interstitial cells of Cajal that pace intestinal contraction. GIST is the definitive success story of targeted therapy in solid tumours: identifying KIT as the driver turned a chemotherapy-resistant cancer into one controlled for years by oral tablets.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Genotype every GIST before starting therapy - it changes drug choice and dose
Who It Affects

Adults, median 60-65; SDH-deficient forms affect children and young adults

Annual Incidence

Approximately 10-15 per million per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Vague abdominal discomfort or early fullness
Gastrointestinal bleeding - black stools, vomiting blood, or iron-deficiency anaemia
A palpable abdominal mass
Nausea or obstruction with larger tumours
Frequently found incidentally at endoscopy or on imaging

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

KIT exon 11 (most common)KIT exon 9PDGFRA including D842VSDHA/B/C/D deficiencyBRAF, NF1 in wild-type disease

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Complete surgical resection without rupture; lymphadenectomy is not required

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

Adjuvant imatinib for three years in high-risk resected disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Imatinib as first-line therapy for advanced disease, dose-adjusted by genotype

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Sunitinib, then regorafenib, then ripretinib in successive lines

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Avapritinib specifically for PDGFRA D842V-mutated disease, which is imatinib-resistant

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

SDH testing in wild-type and paediatric GIST, with different management implications

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Generally good and greatly improved by targeted therapy. Completely resected low-risk tumours are usually cured. Advanced disease is now commonly controlled for several years; median survival on imatinib is around five years, and longer in favourable genotypes such as KIT exon 11.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Next-generation KIT inhibitors designed against specific resistance mutations, and combination strategies to prevent resistance emerging, are the leading directions. SDH-deficient GIST is being studied as a biologically separate disease.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Gastrointestinal Stromal Tumor

Browse All Oncologists

Dr. George D. Demetri

Medical Oncologist

30+ yrs exp

Dana-Farber

Boston, USA

Medical OncologyGISTImatinib Pioneer
Vetted DirectoryConsult Specialist

Dr. Wong Seng Weng

Medical Oncologist

20+ yrs exp

Parkway Cancer Centre

Singapore, Singapore

Medical OncologyGISTTKIs
Vetted DirectoryConsult Specialist

Prof. Peter Reichardt

Oncologist

25+ yrs exp

HELIOS Clinic

Berlin, Germany

Sarcoma OncologyGIST StudiesEORTC
Vetted DirectoryConsult Specialist

Dr. Rajiv Agarwal

Medical Oncologist

20+ yrs exp

Tata Memorial

Mumbai, India

Medical OncologyGISTImatinib
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

rare

Cancer of Unknown Primary (CUP)

rare

Malignant Mesothelioma

rare

Retinoblastoma

rare

Ewing Sarcoma

Independent Tumor Board Review

Facing a Diagnosis of Gastrointestinal Stromal Tumor?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult